Literature DB >> 9731481

The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer.

J Kleeff1, T Ishiwata, H Friess, M W Büchler, M A Israel, M Korc.   

Abstract

Id2 belongs to the Id family of helix-loop-helix (HLH) proteins, which upon heterodimerization with basic HLH proteins prevent basic HLH proteins from DNA binding. Proteins of the Id family act as negative regulatory transcriptional factors, and their expression correlates with cell proliferation and arrested differentiation in many cell lineages. In this study, we characterized the expression of Id2 in normal and cancerous pancreatic tissues. Pancreatic cancers markedly overexpressed Id2 mRNA in comparison to the normal pancreas. Furthermore, there was abundant Id2 immunoreactivity in the cancer cells within the pancreatic tumor mass. In PANC-1 human pancreatic cancer cells, steady-state Id2 mRNA levels increased upon serum addition and decreased after induction of differentiation with either sodium butyrate or 12-O-tetradecanoylphorbol-13-acetate. Inhibition of Id2 expression with Id2 antisense oligonucleotides inhibited the growth of these cells, whereas random and sense oligonucleotides were without effect. These findings suggest that Id2 may have a role in human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731481

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms.

Authors:  M E Massari; C Murre
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Lactation defect in mice lacking the helix-loop-helix inhibitor Id2.

Authors:  S Mori; S I Nishikawa; Y Yokota
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

3.  The MyoD-inducible p204 protein overcomes the inhibition of myoblast differentiation by Id proteins.

Authors:  Chuan-ju Liu; Bo Ding; Hong Wang; Peter Lengyel
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

4.  Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma.

Authors:  Solange Landreville; Duanduan Ma; Jun Wu; J William Harbour
Journal:  Curr Eye Res       Date:  2010-05       Impact factor: 2.424

5.  The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma.

Authors:  Seung-Hee Lee; Ergeng Hao; Alice Kiselyuk; James Shapiro; David J Shields; Andrew Lowy; Fred Levine; Pamela Itkin-Ansari
Journal:  Mol Cancer Res       Date:  2011-04-15       Impact factor: 5.852

6.  Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.

Authors:  M J Gray; N A Dallas; G Van Buren; L Xia; A D Yang; R J Somcio; P Gaur; L S Mangala; P E Vivas-Mejia; F Fan; A M Sanguino; G E Gallick; G Lopez-Berestein; A K Sood; L M Ellis
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

7.  [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].

Authors:  E Noetzel; J Veeck; F Horn; A Hartmann; R Knüchel; E Dahl
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

8.  Snail interacts with Id2 in the regulation of TNF-α-induced cancer cell invasion and migration in OSCC.

Authors:  Jing-Ping Zhou; Zhen-Lin Gao; Mei-Ling Zhou; Meng-Ying He; Xiao-Hui Xu; De-Tao Tao; Cong-Chong Yang; Lai-Kui Liu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

9.  Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F.

Authors:  Silvia Coma; Dhara N Amin; Akio Shimizu; Anna Lasorella; Antonio Iavarone; Michael Klagsbrun
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

Review 10.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.